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move, but some had ascites, pleural effusion, jaundice, dyspnea (3-10%), and used
narcotic (13%). At first visit, as old as age 97 received care (mean age 54.8/14.3;
ranged 1-97), and lung, hepatobiliary, colon, gastric, breast and pancreatic cancer
were comprised of 80% of cancers. Among these about 40-50% had poor perfor-
mance status (ECOG 2-4). CONCLUSIONS: In consideration of the size of the center
and non-insured, offering cytostatic therapy received with remarkable attention by
the patients previously treated with cytotoxic therapy. Further research is needed
to investigate cons and pros of cytostatic therapy.
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OBJECTIVES: In some BCC patients, tumors may progress to locally advanced dis-
ease or become metastatic (aBCC). BCCNS (Gorlin syndrome) is a rare genetic con-
dition associated with life-long occurrence of multiple BCCs. Surgical treatments
may cause disfiguring scars. The patient experience for those with aBCC and BC-
CNS is not well understood. Qualitative research was conducted to develop a PRO
questionnaire for this population. METHODS: Concept elicitation interviews were
conducted in aBCC or BCCNS patients  18 yr and physicians using an interview
guide containing open-ended questions about symptom impact on functioning
and well-being. Results from patient interviews were used to develop draft ques-
tionnaires. Cognitive debriefing interviews were conducted to finalize the
questionnaires. RESULTS: Thirty patients were interviewed [14 aBCC (8 locally
advanced and 6 metastatic; 73% male, mean age 64) and 16 BCCNS (50% male, mean
age 51)]. Patients experience a variety of disease symptoms including pain, swell-
ing, bleeding, and itching. Physical appearance, specifically scarring and disfigure-
ment, affected 73% of patients. 80% of patients made lifestyle changes (avoided
outdoor activities and intimate relationships). Emotional effects, including worry
about when/where the next BCC would appear, were evident in BCCNS patients
(80%). Physicians (n4) noted aBCC patients worry about cancer and the possibility
of more tumors, while BCCNS patients are concerned about tumor recurrence,
multiple surgeries and disfigurement. Based on interview results, separate aBCC
and BCCNS questionnaires were developed. Ten cognitive-debrief interviews were
conducted to evaluate content and clarity of draft questionnaires. The question-
naires were easy to complete and items were relevant. Minor revisions were made.
The final questionnaires include questions about symptoms, appearance, emo-
tions, worry, lifestyle changes, concerns, and treatment satisfaction.
CONCLUSIONS: There are significant and unique impacts to appearance, daily and
emotional functioning, and HRQoL in aBCC and BCCNS patients. An ongoing vali-
dation study will examine psychometric properties of the questionnaires.
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OBJECTIVES: FDA and EMA have created guidelines for PRO label claims. However,
there have been few PRO-based label claims in oncology (Gnanasakthy, et al., 2012)
since the release of the FDA guidelines. The objective of this research was to ex-
plore factors that might predict regulatory success for PROs. We developed a reg-
ulatory success gradient, and used factors based on literature review, expert inter-
views, and the FDA Guidances to predict success. METHODS: Using a case-control
approach, 10 oncology medications with PRO labels came from two sources: 1) a
review of PROs in oncology labels (Gondek et al, 2007), and 2) a proprietary database
(http://www.mapi-prolabels.org/) containing a list of PRO-based labels. Six controls
were oncology medications with the same indication and mechanism of action, but
without PRO data in the label. Regulatory success was defined from none (no PRO in
the label), through minimal, mild, and moderate, to great success (PRO labeling in
the indication section). Independent factors, derived from literature review, expert
interviews, and the PRO Guidances, possibly related to regulatory success included
conceptual fit, study quality, conformity to PRO Guidance (content validity), psy-
chometrics score, and other PRO characteristics, were evaluated. RESULTS: No
medication achieved great PRO labeling success. Only three medications achieved
moderate regulatory success, seven achieved mild, and five achieved minimal suc-
cess. None of the factors identified as potentially related to regulatory success were
significantly correlated with it (Spearman correlations): Other PRO Characteristics
(0.33), Conceptual Fit (0.09), Study Quality (-0.13), Psychometrics (-0.18), and Con-
formity to the PRO Guidance (0-0.02). CONCLUSIONS: Despite widespread use of
PROs in oncology, very few labels actually include PRO-based results, and further-
more, no medications achieved great success and only three moderate success in
labeling. Based on our regulatory success gradient, driving factors leading to regu-
latory success have yet to be identified.
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OBJECTIVES: Lung cancer is one of the most common high incidence and mortality
cancers. Many lung cancer patients (LCPs) receive chemotherapy not only for cu-
rative treatment, but also to palliate symptoms and maintain or even improve their
quality of life (QOL). Though the impact of substances and duration of chemother-
apy on progression-free and overall survival is intensively investigated, there is
currently only little knowledge on patients’ QOL in regard to the number of CT-lines
administered. METHODS: By means of computer-based patient-reported outcome
monitoring LCPs receiving ambulant chemotherapy (adjuvant or palliative) com-
pleted the internationally validated EORTC QLQ-C30, supplemented by two addi-
tional questions concerning taste alterations. Statistical analysis comprised mixed
linear models to calculate change rates over time and differences between chemo-
therapy lines. RESULTS: A total of 175 LCPs (32% female, on average 68 years old (
10.4 SD) and 5 ( 4.5 SD) assessments/patient) participated in repeated QOL-assess-
ment during ambulant chemotherapy administration. Twenty percent of LCPs re-
ceived adjuvant chemotherapy, 73.1% 1st line palliative chemotherapy and 6.9% 2nd
or above line chemotherapy. 70.7% were diagnosed with NSCLC, 21.0 % with SCLC
and 8.3% with other types of lung cancer. Symptom trajectories during adjuvant
chemotherapy did not show a significant change in QOL-scores. LCPs receiving 1st
line palliative chemotherapy experienced improvement concerning sleep distur-
bances (-1.9 points/month, p.009), but deteriorations in regard to appetite loss
and taste alterations (2.8 points/month, p.001, respectively), constipation (1.8
points/month, p.020) and financial impact (1.3 points/month, p.038); 2nd or
above line palliative chemotherapy was associated with stronger symptom burden
than adjuvant or 1st line palliative chemotherapy in most of the EORTC QLQ-C30
domains (e.g. physical, emotional and cognitive functioning, pain and appetite
loss). CONCLUSIONS: Though aggressive, adjuvant treatment did not endanger
patients’ QOL. 1st line palliative chemotherapy proved to be helpful in maintaining
and stabilizing patients’ QOL, since deteriorations have been limited.
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Appropriate utility values for disease states in metastatic castration-resistant pros-
tate cancer (mCRPC) have been contentious in recent economic models submitted
to NICE and other HTA bodies. The validity of mapping algorithms beyond the
range of original data in less symptomatic patients and the evolution of utility once
life-extending treatments have failed, were both considered areas of uncertainty.
OBJECTIVES: To construct and validate a prediction model of preference-adjusted
health status (EQ-5D) for metastatic castration-resistant prostate cancer (mCRPC)
patients using FACT-P (Functional Assessment of Cancer Therapy–Prostate).
METHODS: Observational study conducted in 47 centres across 6 countries (Bel-
gium, France, Germany, Sweden, The Netherlands, UK) collected HRQoL data for
699 patients with confirmed mCRPC and documented disease progression. Utility
values were derived from EQ-5D profiles based on a UK-specific EQ-5D value set (1).
Predictive validity of the 5 FACT-P subscales, patient demographics, co-morbidities
and prior chemotherapy for utility values was tested using ordinary least square
(OLS), median, Gamma and Tobit multivariate regression models. RESULTS: At the
time of assessment, mean age, mean time since diagnosis and failure on androgen-
deprivation therapy were 72.1, 6.6 and 4.1 years respectively; 32% of patients were
treated with chemotherapy, 24% had prior chemotherapy, and 43% were chemo-
therapy naive. At diagnosis, 35.9% of patients had metastases and 84.1% had Glea-
son score 7. Mean FACT-P and EQ-5D utility were 104.0 and 0.67 respectively.
OLS-regression was the best-performing model, explaining 61% of the observed
EQ-5D variation. All FACT-P subscales were significantly predictive. The physical
(coefficient0.023,p0.0001) and functional (0.011,p0.0001) well-being subscales
had the highest explanatory value. Age, co-morbidities and prior chemotherapy
did not add additional explanatory value. CONCLUSIONS: The developed algo-
rithms enable translation of cancer-specific health-related quality of life measures
to preference-adjusted health status in mCRPC-patients. Findings will help to de-
velop health status adjustments in cost-utility analyses used in future HTA’s.
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OBJECTIVES: Malignant ascites (MA) is associated with poor prognosis and limited
palliative therapeutic options. Therefore a change in patients’ health-related qual-
ity of life (HRQoL) is of particular importance to demonstrate added value of a new
treatment to the patient-reported outcomes (PRO). Moreover how fast the change
occurs can be as important as the simple occurrence of a meaningful change in
HRQoL. Following demonstration of superiority on puncture-free survival of catu-
maxomab plus paracentesis vs paracentesis alone, this study aimed to compare
time to deterioration in HRQoL between both treatment groups by using survival
analysis techniques.METHODS: In a randomized, multi-center, phase II/III study in
patients with MA, HRQoL was measured by using the European Organization for
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